Duopharma Biotech Bhd Stock Beta
7148 Stock | 1.23 0.03 2.38% |
Duopharma Biotech Bhd fundamentals help investors to digest information that contributes to Duopharma Biotech's financial success or failures. It also enables traders to predict the movement of Duopharma Stock. The fundamental analysis module provides a way to measure Duopharma Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Duopharma Biotech stock.
Duopharma |
Duopharma Biotech Bhd Company Beta Analysis
Duopharma Biotech's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Competition |
In accordance with the recently published financial statements, Duopharma Biotech Bhd has a Beta of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Pharmaceuticals (which currently averages 0.0) industry. The beta for all Malaysia stocks is 100.0% lower than that of the firm.
Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
All Next | Launch Module |
Duopharma Fundamentals
Return On Equity | 10.93 | |||
Current Valuation | 1.78 B | |||
Price To Book | 2.32 X | |||
Price To Sales | 2.12 X | |||
Revenue | 639.17 M | |||
EBITDA | 121.38 M | |||
Net Income | 82.98 M | |||
Cash And Equivalents | 31.5 M | |||
Total Debt | 297.8 M | |||
Cash Flow From Operations | 43.2 M | |||
Market Capitalization | 1.56 B | |||
Total Asset | 1.16 B | |||
Z Score | 3.0 | |||
Annual Yield | 0.04 % | |||
Net Asset | 1.16 B | |||
Last Dividend Paid | 0.095 |
About Duopharma Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Duopharma Biotech Bhd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Duopharma Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Duopharma Biotech Bhd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Duopharma Stock
Duopharma Biotech financial ratios help investors to determine whether Duopharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Duopharma with respect to the benefits of owning Duopharma Biotech security.